ArticleTherapeutic advances in medical oncology2024
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 15 citations in OpenAlex.
- A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.Future oncology (London, England) · 2025Trial
- Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from Japan.Advances in therapy · 2026Article
- Liquid-liquid phase separation-related gene signature characterizes prognostic subtypes and therapeutic sensitivities in gastric cancer.Translational cancer research · 2026Article
- Risk factors and clinical outcomes associated with leptomeningeal carcinomatosis in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023.Therapeutic advances in gastroenterology · 2026Article
- Current Role of Artificial Intelligence in the Management of Gastric Cancer.Biomedicines · 2025Review
- Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer.BMC gastroenterology · 2025Article
- Comparison of laparoscopic and open total gastrectomy with D2 lymphadenectomy for gastric cancer: a propensity score matched study.BMC surgery · 2025Article
- Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.The oncologist · 2025Observational
- Stereotactic body radiation therapy for spinal metastases from gastrointestinal primary cancers.Journal of neuro-oncology · 2025Article
- Total gastrectomy and extended D2 lymphadenectomy for primary gastric squamous cell carcinoma: A case report.Oncology letters · 2025Article
- Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer.Therapeutic advances in medical oncology · 2025Article
- Systemic therapy strategies for elderly patients with gastric cancer.Therapeutic advances in medical oncology · 2025Review
- Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023.Therapeutic advances in medical oncology · 2025Article
- Tumor Characteristics and D2 Lymph Node Involvement in Gastric Cancer: A Clinicopathological Analysis (2018-2023) :.Galen medical journal · 2025Article
- Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.Scientific reports · 2024Observational
- Review
- Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study.Journal of gastric cancer · 2023Article
- Body Mass Index (BMI) as a Prognostic Factor Influencing Outcomes of Gastric Cancer Resection Including Curative Gastrectomy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent trials have reported a median overall survival (OS) of 11-17 months in patients with advanced gastric cancer (AGC). However, it is unclear how recently approved drugs contribute to patient prognosis. Objectives: We aimed to evaluate the characteristics and survival in patients with AGC over the past 15 years. Design: Retrospective study. Methods: We evaluated data of 1355 patients with AGC who received first-line chemotherapy between January 2005 and March 2019 at a single institution. We compared the characteristics and survival rates across four periods: January 2005-December 2007 (period A), January 2008-February 2011 (period B), March 2011-May 2015 (period C), and June 2015-March 2019 (period D). The median follow-up duration was 13.1 months, with 312, 333, 393, and 317 patients in periods A, B, C, and D, respectively. Results: There were no significant differences in patient characteristics between the four periods, except for the proportion of patients who underwent prior gastrectomy and human epidermal growth factor receptor 2 (HER2) testing. Patients in period D had significantly longer OS than those in period A [median: 15.7 Conclusion: Clinical strategy changes, including gastrectomy, HER2 testing, and approval of new drugs, may be associated with improved OS in patients with AGC. In the last 4 years, a remarkable improvement has been observed in patients with LM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.